WGRX Wellgistics Health, Inc.

CIK 0002030763 50 ready 8-Ks latest June 2, 2026, 4:15 PM ET RSS · JSON

Activity: ELEVATED 9 filings / 30d vs 3 baseline Risk accumulating: auditor change (4)

Ready 8-Ks 50

Latest filing June 2, 2026, 4:15 PM ET

Top materiality 0.85

Event mix other_material ×30 · leadership ×6 · debt ×5

Sentiment 15 pos · 7 neg · 28 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for WGRX

Highest-materiality recent filing

Wellgistics Health enters binding term sheet for DelivMeds AI; announces 1-for-50 reverse stock split

May 21, 2026, 6:51 AM ET M&A materiality 0.85 neutral item 1.01 item 2.03 item 3.02 item 3.03 item 5.03 item 5.02 item 9.01 ◈ executive_change◈ Governance Changes

Binding term sheet with Datavault AI (DVLT), Scilex (SCLX) and others to form DelivMeds AI; combined asset value expected $4B (subject to fairness opinion).
Existing public stockholders projected to retain ~10.4% of common post-conversion; new parties to own ~89.6% via convertible preferred.

Read filing →

June 2, 2026, 4:15 PM ET debt materiality 0.75 positive item 9.01

Wellgistics Health issues $21M convertible debt, raises $6.5M new capital, refinances all outstanding convertible debt

New $21M oversubscribed convertible debt refinances all outstanding convertible debt; no interest; converts at $6.00/share.
May 29, 2026, 5:30 PM ET debt materiality 0.75 neutral item 1.01 item 3.02 item 7.01 item 9.01

Wellgistics Health raises $16.9M via convertible notes at 20% OID; majority shareholders lock up shares

Notes aggregate principal $21.1M for $16.9M cash (20% OID); zero interest; mature in 12 months.
May 21, 2026, 4:10 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Wellgistics Health announces strategic moves: DelivMeds AI, QOLPOM patents, Tollo Health stake, and share restructuring

Expanded Datavault license and DelivMeds AI create IP for tokenized healthcare data management via EinsteinRx™.
May 21, 2026, 6:51 AM ET M&A materiality 0.85 neutral item 1.01 item 2.03 item 3.02 item 3.03 item 5.03 item 5.02 item 9.01 ◈ executive_change◈ Governance Changes

Wellgistics Health enters binding term sheet for DelivMeds AI; announces 1-for-50 reverse stock split

Binding term sheet with Datavault AI (DVLT), Scilex (SCLX) and others to form DelivMeds AI; combined asset value expected $4B (subject to fairness opinion).
May 19, 2026, 5:11 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

Wellgistics Q1 revenue $0.93M, net loss $7.7M; terminates Neuritek/WellCare LOIs; guides Q2 ~$1.78M

Revenue $0.93M in Q1 2026 vs $0.49M Q4 2025; expects Q2 rev $1.78M (with $0.86M recognized through May 18).
May 7, 2026, 7:59 PM ET debt materiality 0.75 negative item 1.01 item 9.01 ◈ Material Agreements

Wellgistics Health subsidiary enters forbearance agreement on $1.77M debt

Wellgistics, LLC acknowledges $1.77M owed to Marco Capital under Nov 2024 loan; MCI forbears through June 15, 2026.
April 21, 2026, 7:59 PM ET other material materiality 0.75 negative item 3.01 item 1.01 item 3.02 item 7.01 item 9.01 ◈ Material Agreements

Wellgistics receives Nasdaq deficiency notice; forms JV with KareRx hub

Received Nasdaq deficiency letter on Apr 13, 2026 for failing minimum $2.5M stockholders' equity; equity was -$12.4M.
April 17, 2026, 7:59 PM ET M&A materiality 0.75 positive item 1.01 item 3.02 item 7.01 item 9.01 ◈ Material Agreements

Wellgistics Health forms joint venture with KareRx Hub, issuing up to $2M in stock for 51% stake

Wellgistics holds 51% membership interest in new LLC Healthstar; Kare Rx Hub holds 49%.
April 9, 2026, 7:59 PM ET other material materiality 0.65 positive item 1.01 item 8.01 ◈ Material Agreements

Wellgistics terminates settlement with Silverback Capital; no further share issuance under Section 3(a)(10)

Company terminated Settlement Agreement with Silverback Capital Inc., effective April 3, 2026.
April 7, 2026, 7:59 PM ET debt materiality 0.60 neutral item 1.01 item 2.03 item 3.02 item 9.01 ◈ Debt Financings◈ Material Agreements

Wellgistics Health issues $1.25M in promissory notes at 20% discount to accredited investors

Company entered Note Purchase Agreement for up to $1,250,000 aggregate principal; purchase price $1,000,000 (20% OID).
February 13, 2026, 6:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.02 item 7.01 item 8.01 item 9.01 ◈ Material Agreements

Wellgistics settles $10.7M liabilities via equity at $0.25–$2.25/share; appoints consulting CBO

Settled ~$10.7M liabilities with Silverback Capital via court-approved Section 3(a)(10) share issuance.
February 9, 2026, 6:59 PM ET other material materiality 0.65 positive item 5.02 item 7.01 item 9.01

Wellgistics Health partners with NFL Alumni Health to deploy AI pharmacy tech for former NFL players

Partnership leverages EinsteinRx AI platform and PharmacyChain smart contracts for healthcare optimization.
February 5, 2026, 6:59 PM ET leadership materiality 0.65 neutral item 5.02 item 9.01

Two directors resign from Wellgistics Health board effective Feb 1, 2026

Steven Lee (Ethics Committee) and Howard Doss (Audit Committee chair) resigned immediately.
January 20, 2026, 6:59 PM ET debt materiality 0.65 negative item 1.01 item 2.03 item 3.02 item 9.01 ◈ Material Agreements ×2◈ Debt Financings

Wellgistics Health issues up to $8.125M secured convertible notes at 20% OID

Issued $8.125M aggregate principal of secured convertible notes; purchase price $6.5M (20% OID).
January 8, 2026, 6:59 PM ET other material materiality 0.75 neutral item 1.01 item 2.03 item 3.02 item 7.01 item 9.01 ◈ Material Agreements ×2◈ Debt Financings

Wellgistics Health issues $3.125M convertible notes at 20% OID; sets 2026 target of 500 pharmacy onboardings/month

Issued up to $3,125,000 aggregate principal convertible notes; purchase price $2.5M (20% original issue discount).
December 16, 2025, 6:59 PM ET regulatory materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices

Wellgistics Health receives Nasdaq bid-price deficiency notice; 180-day cure period through June 8, 2026

Stock closed below $1.00 for 30 consecutive business days (Oct 27–Dec 9, 2025); violates Nasdaq Listing Rule 5550(a)(2).
November 26, 2025, 6:59 PM ET other material materiality 0.65 positive item 1.01 item 7.01 item 9.01

Wellgistics licenses DataVault AI smart contract IP for PharmacyChain; $2.5M upfront plus royalties

Upfront license fee of $2.5M due by Dec 31, 2025; ongoing 13% royalty on PharmacyChain net profit.
November 25, 2025, 6:59 PM ET other material materiality 0.65 positive item 1.01 item 7.01 item 9.01

Wellgistics Health pays $2.5M for exclusive license of DataVault AI patents for PharmacyChain

License fee of $2.5M to DataVault AI, payable by Dec 31, 2025; plus 13% royalty on net profit from PharmacyChain.
November 20, 2025, 6:59 PM ET earnings materiality 0.80 negative item 2.02 item 7.01 item 9.01

Wellgistics Q3 net loss widens to $33.9M ($0.46/share) on stock-based comp

Q3 2025 net operating loss $33.878M vs $1.867M in Q3 2024; net loss per share $0.46 vs $0.04.
November 17, 2025, 6:59 PM ET regulatory materiality 0.70 negative item 4.01 item 9.01 ◈ Auditor Changes ×2

Auditor UHY resigns citing former CEO resignation info; Suri & Co. re-engaged

UHY LLP resigned as auditor on Nov 11, 2025 due to information from former CEO's resignation not yet investigated.
October 17, 2025, 7:59 PM ET leadership materiality 0.80 neutral item 7.01 item 9.01

Wellgistics Health re-appoints Prashant Patel as interim CEO; multiple executive departures

Prashant Patel re-appointed President, Interim-CEO, and Board member after August 2025 resignation.
October 10, 2025, 7:59 PM ET leadership materiality 0.85 negative item 5.02

CEO, COO, CFO resign at Wellgistics Health; interim CFO appointed

CEO Brian Norton, COO Tony Madsen, and CFO Mark DiSiena resigned effective Oct. 6, 2025.
October 6, 2025, 7:59 PM ET leadership materiality 0.75 neutral item 5.02 item 9.01

Wellgistics Health removes two directors, appoints four new directors and a President

Rebecca Shanahan and Michael Peterson removed as directors effective Oct 1, 2025 by majority stockholder consent.
October 1, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 7.01 item 9.01

Wellgistics prices $5M offering (7.14M shares + warrants at $0.70), partners with TheracosBio on Brenzavvy

Public offering of 7,142,862 common shares and warrants to purchase an equal number, at $0.70 per unit; gross proceeds ~$5M.
August 14, 2025, 7:59 PM ET other material materiality 0.70 positive item 1.02 item 5.02 item 7.01 item 9.01

Wellgistics Health terminates $50M ELOC, President resigns, launches XRP payment program

Terminated $50M equity purchase agreement with Hudson Global Ventures without penalty; no termination fees.
July 30, 2025, 7:59 PM ET other material materiality 0.70 positive item 1.01 item 7.01 item 9.01

Wellgistics Health converts $8.1M debt to equity, amends acquisition payment terms

Remaining $8.14M closing cash payment converted into 7,606,785 shares of common stock; reduces short-term debt.
April 11, 2025, 7:59 PM ET M&A materiality 0.75 neutral item 1.01 item 2.03 item 3.02 item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Wellgistics Health to acquire Peek Healthcare for $2M cash, $6M note, and shares

Merger: Peek acquired for $2M cash (adjusted) + $6M note (4.5% for 3 years) + 1,777,778 shares; 1,270,163 earn-out subject to $8.8M revenue target by Dec 2027.
March 27, 2025, 7:59 PM ET other material materiality 0.70 positive item 3.02 item 7.01 item 9.01

Wellgistics grants 19.8M shares of restricted stock; reports pro forma 2024 revenue of $45.7M

Granted 19,764,108 restricted shares under the 2023 Equity Plan, including 9M to CEO vesting on financial metrics for FY2025-2027.
March 21, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 7.01 item 9.01

Wellgistics Health enters consulting deal with Draper (100k shares) and reports SOC 2 Type 1 compliance

Entered consulting agreement with Draper, Inc. for investor relations and business development services; initial term 3 months, automatic monthly renewal.
March 6, 2025, 6:59 PM ET leadership materiality 0.70 positive item 1.01 item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Wellgistics Health appoints Brian Norton as CEO, partners with Protega to distribute ROXYBOND

Brian Norton promoted to CEO, succeeding Timothy Canning; no disagreement cited.
February 28, 2025, 6:59 PM ET other material materiality 0.65 positive item 1.01 item 7.01 item 8.01 item 9.01

Wellgistics Health partners with Tollo Health to market medical foods for GLP-1 side effects and Long COVID

Consulting agreement with Hudson Global Ventures: $250,000 fee + 52,000 shares for 30-day advisory services.